

## From the CEO's Desk

We had an exciting and productive second quarter. That progress continues on every front within the Company as we commercialize our current S-Series device and, at the same time, lay the groundwork for what we expect will be an aggressive and successful roll-out of our next-generation B-Series device, starting in the next few months pending U.S. Food and Drug Administration approval. Grateful to have you with us on this journey.



Adrian Mendes, CEO

## What Investors Should Know

### **Renowned Surgical Oncologist, Dr. Ted James, Joins Perimeter as Chief Medical Officer**

Dr. James' addition to the Perimeter management team strengthens its medical strategy and will help accelerate adoption of its technology as we look forward to commercializing our AI enabled B-Series device. Dr. James recently became System Physician Executive of the Endeavor Health Cancer Institute after serving as Chief of Breast Surgical Oncology and Director of the Breast Center at Beth Israel Deaconess Medical Center (BIDMC), where he oversaw the growth of a nationally accredited multidisciplinary breast program and developed an NIH-funded research portfolio. He was also Vice Chair of Academic Affairs in the Department of Surgery at BIDMC and an Associate Professor of Surgery at Harvard Medical School. Dr. James received his medical degree from Drexel University, completed his surgical residency at NYU (North Shore-Long Island Jewish), and trained in surgical oncology at Roswell Park Cancer Institute. He also holds a Master of Science in Healthcare Management from the Harvard T.H. Chan School of Public Health.

### **Latest Corporate Updates**

- Perimeter Medical Imaging AI reported second quarter financial results on August 26, 2025
- Stronger S-Series system utilization, with significantly more intraoperative OCT imaging procedures performed by existing surgeon users, at a higher price per procedure
- Abbey Goodman appointed as Vice President, Sales, and Paolo DiPasquale as Vice President, Corporate Development
- Perimeter launches its Industry Advisory Board with Diana Chan as Chair

### **NEW Pivotal Trial Case Study- Dr. Marie Lee's Success with OCT & ImgAssist**

Accurate intraoperative detection resulted in the removal of all residual disease at the point of care, without the need for any reoperations.

### **Providence St. Joseph's Roy and Patricia Disney Family Cancer Center adopts S-Series OCT across its hospitals and affiliates**

### **Financing closes**

Perimeter Announces Closing of Final Tranche of Prospectus Offering for \$2.25 Million; Total Gross Proceeds of \$5.35 Million Raised Under Prospectus Offering

### **Huge Success at American Society of Breast Surgeons (ASBrS) Conference**

Detailed Results from B-Series OCT with ImgAssist AI 2.0 Pivotal Trial Presented at ASBrS 2025

### **Perimeter Medical Imaging AI Accepted Into NVIDIA Connect Program**

This collaboration represents a pivotal step in Company's mission to advance surgical oncology

## Hot off the Press



### **Med City Dallas Adopts Perimeter's S-Series Technology**



### **HCA Rose Medical Center, Denver, first in Colorado to adopt S-Series OCT Technology**



### **Adrian Mendes speaks on the Crux of Medtech Podcast with Henry Norton**



### **Perimeter Medical Imaging AI Presented at the Life Sciences Virtual Investor Forum**



### **Perimeter Launches OCT-Tissue Registry to Power AI and Imaging Innovation**



### **Partnership with Intermountain Health to Study the Potential Clinical and Socio-Economic Benefits of Using OCT and AI to Reduce Cancer Reoperations**




### **HonorHealth Deploys S-Series OCT Tech (First in Arizona)**




### **Awards**

Perimeter awarded 2025 TAG Awards in the MedTech category, Pinnacle Award in Healthcare and Technology categories.



### **Adrian Mendes speaks on the State of Medtech Podcast with Omar Khateeb**



### **Adrian Mendes on the Armstrong Williams Show**

## What's Next

<p><b>September 26-27</b></p> <p><b>TME/Aptitude Health Conference</b></p>	<p><b>October 2</b></p> <p><b>Perimeter participates in MedCity Dallas' BCAM event</b></p>
<p><b>October 20-21</b></p> <p><b>American Society of Breast Surgeons (ASBrS) Strategic Futures Forum</b></p>	

## Quick Links

- Investor Deck
- SEDAR+ Files
- News Room
- Leadership Bios
- Contact Investor Relations

You can also sign up to get Perimeter [news release alerts](#) delivered directly to your email or check out the news feed on our [investor website](#).

*This information is intended for an investor audience and not for use by healthcare professionals. The information contained herein should not be used to guide clinical practice.*

### **S-Series OCT**

The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest.

The S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established.

For full information on unapproved/off-label uses, visit: [perimetermed.com/disclosures](https://perimetermed.com/disclosures) or contact [medicalaffairs@perimetermed.com](mailto:medicalaffairs@perimetermed.com).

### **B-Series OCT**

The Perimeter B-Series OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer aided detection algorithm which identifies and marks focal areas suspicious for breast cancer and is used concurrently with physician interpretation of the images. B-Series OCT is intended for use in conjunction with other standard methods for evaluation of the margins of an excised lumpectomy specimen during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.

**Perimeter B-Series OCT is not available for sale in the United States. CAUTION - Investigational device. Limited by U.S. law to investigational use**

*You are receiving this email because you signed up for news alerts from Perimeter Medical Imaging AI. Please use the "Unsubscribe Preferences" link below if you wish to opt out of this e-newsletter.*